Lithium, Antipsychotics, and Risk of Psoriasis
暂无分享,去创建一个
F. Curtin | S. Jick | C. Meier | Y. Brauchli
[1] F. Curtin,et al. Association between beta‐blockers, other antihypertensive drugs and psoriasis: population‐based case–control study , 2008, The British journal of dermatology.
[2] F. Curtin,et al. Association between use of thiazolidinediones or other oral antidiabetics and psoriasis: A population based case-control study. , 2008, Journal of the American Academy of Dermatology.
[3] L. Fry,et al. Triggering psoriasis: the role of infections and medications. , 2007, Clinics in dermatology.
[4] Khusru Asadullah,et al. Immunopathogenesis of psoriasis , 2007, Experimental dermatology.
[5] C. Griffiths,et al. Pathogenesis and clinical features of psoriasis , 2007, The Lancet.
[6] Z. Herman,et al. Cytokines in schizophrenia and the effects of antipsychotic drugs , 2006, Brain, Behavior, and Immunity.
[7] J. Koo,et al. The mechanism of lithium and beta-blocking agents in inducing and exacerbating psoriasis. , 2006, Journal of drugs in dermatology : JDD.
[8] D. Margolis,et al. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. , 2005, Archives of dermatology.
[9] H. Richards,et al. Psychologic factors in psoriasis: consequences, mechanisms, and interventions. , 2005, Dermatologic clinics.
[10] W. Nolen,et al. Evidence that the immunopathogenic mechanism of lithium-induced psoriasis differs from that of regular psoriasis. , 2005, Bipolar disorders.
[11] L. Naldi,et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. , 2005, The Journal of investigative dermatology.
[12] L. Naldi,et al. Epidemiology of psoriasis. , 2004, Current drug targets. Inflammation and allergy.
[13] D. Margolis,et al. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. , 2003, Archives of dermatology.
[14] A. Latini,et al. Psoriasis during therapy with olanzapine. , 2003, European journal of dermatology : EJD.
[15] Corri Black,et al. Validity of the General Practice Research Database , 2003, Pharmacotherapy.
[16] K. Orr,et al. Paroxetine-associated psoriasis. , 2002, The American journal of psychiatry.
[17] E M Farber,et al. The prevalence of psoriasis in the world , 2001, Journal of the European Academy of Dermatology and Venereology : JEADV.
[18] Franco Alessandrini,et al. Exacerbation of chronic large plaque psoriasis associated with Olanzepine therapy , 2000, Journal of the European Academy of Dermatology and Venereology : JEADV.
[19] N. Tsankov,et al. Drug-Induced Psoriasis , 2000 .
[20] N. Tsankov,et al. Drugs in exacerbation and provocation of psoriasis. , 1998, Clinics in dermatology.
[21] L. Naldi,et al. Dietary factors and the risk of psoriasis. Results of an Italian case–control study , 1996, The British journal of dermatology.
[22] A. Winston,et al. Fluoxetine-Induced Psoriasis , 1992, The Annals of pharmacotherapy.
[23] E. Orenberg,et al. Drugs in exacerbation of psoriasis. , 1986, Journal of the American Academy of Dermatology.
[24] E. Christophers,et al. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. , 1985, Journal of the American Academy of Dermatology.
[25] D. Sarantidis,et al. A Review and Controlled Study of Cutaneous Conditions associated with Lithium Carbonate , 1983, British Journal of Psychiatry.
[26] S. Halevy,et al. Drug exposure and psoriasis vulgaris: case-control and case-crossover studies. , 2005, Acta dermato-venereologica.
[27] N. Tsankov,et al. Drug-induced psoriasis. Recognition and management. , 2000, American journal of clinical dermatology.
[28] L. G. García Rodríguez,et al. Use of the UK General Practice Research Database for pharmacoepidemiology. , 1998, British journal of clinical pharmacology.
[29] H. Tagami,et al. Triggering factors. , 1997, Clinics in dermatology.